Irinotecan--második vonalbeli kezeléssel szerzett tapasztalatok elórehaladott colorectalis daganatokban.

Translated title of the contribution: [Irinotecan--experience with second-line treatment in advanced colorectal cancer] .

K. Kristó, J. Izsó, G. Balatoni, J. Lohinszky, E. Farczádi, J. Szántó, A. P. Kofi, T. Pintér

Research output: Contribution to journalArticle

Abstract

The prognosis for patients with advanced colorectal cancer who fail to respond to a 5-FU based therapy is poor. About 7% response rate can be achieved with second line therapeutic regiments, the overall survival is about 6-7 months. The aim of authors was to assess the efficacy and toxicity profile of irinotecan (CAMPTO) in patients with advanced colorectal cancer, resistant to 5-FU based chemotherapy. From October 1996 to November 1998 19 previously treated metastatic colorectal cancer patients with documented progression were recruited. Irinotecan was given at a dose of 350 mg/m2 i.v. over 90 min. every 3 week. Tumor response and toxicity were assessed using WHO criteria. Median age: 59.7 years (42-72). Tumor sites: 12/19 colon, 7/19 rectum. 11/19 patients had 1 metastatic site, 8/19 had 2 or more metastatic sites. CR: 0/19, PR: 3/19, MR: 2/19, SD: 10/19, PD: 4/19. Median time to progression was 9.1 months (range 1.5-22). The overall median survival was 15.5 months (range 2.5-37). Grade 3-4 delayed diarrhoea occurred in 26.3% of patients. Grade 3 neutropenia occurred in 15.7% of patients. Preliminary results confirm the clinical value of irinotecan in 5-FU resistant metastatic colorectal cancer with tolerable toxicity profile. Irinotecan should be considered as the basic chemotherapeutic agent for second line treatment of metastatic colorectal cancer.

Original languageHungarian
Pages (from-to)1817-1820
Number of pages4
JournalOrvosi Hetilap
Volume141
Issue number33
Publication statusPublished - Aug 13 2000

Fingerprint

irinotecan
Colorectal Neoplasms
Fluorouracil
Therapeutics
Survival
Neutropenia
Rectum
Diarrhea
Neoplasms
Colon

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Irinotecan--második vonalbeli kezeléssel szerzett tapasztalatok elórehaladott colorectalis daganatokban. / Kristó, K.; Izsó, J.; Balatoni, G.; Lohinszky, J.; Farczádi, E.; Szántó, J.; Kofi, A. P.; Pintér, T.

In: Orvosi Hetilap, Vol. 141, No. 33, 13.08.2000, p. 1817-1820.

Research output: Contribution to journalArticle

Kristó, K, Izsó, J, Balatoni, G, Lohinszky, J, Farczádi, E, Szántó, J, Kofi, AP & Pintér, T 2000, 'Irinotecan--második vonalbeli kezeléssel szerzett tapasztalatok elórehaladott colorectalis daganatokban.', Orvosi Hetilap, vol. 141, no. 33, pp. 1817-1820.
Kristó K, Izsó J, Balatoni G, Lohinszky J, Farczádi E, Szántó J et al. Irinotecan--második vonalbeli kezeléssel szerzett tapasztalatok elórehaladott colorectalis daganatokban. Orvosi Hetilap. 2000 Aug 13;141(33):1817-1820.
Kristó, K. ; Izsó, J. ; Balatoni, G. ; Lohinszky, J. ; Farczádi, E. ; Szántó, J. ; Kofi, A. P. ; Pintér, T. / Irinotecan--második vonalbeli kezeléssel szerzett tapasztalatok elórehaladott colorectalis daganatokban. In: Orvosi Hetilap. 2000 ; Vol. 141, No. 33. pp. 1817-1820.
@article{4ad1155d00f34481a812a2addfb18366,
title = "Irinotecan--m{\'a}sodik vonalbeli kezel{\'e}ssel szerzett tapasztalatok el{\'o}rehaladott colorectalis daganatokban.",
abstract = "The prognosis for patients with advanced colorectal cancer who fail to respond to a 5-FU based therapy is poor. About 7{\%} response rate can be achieved with second line therapeutic regiments, the overall survival is about 6-7 months. The aim of authors was to assess the efficacy and toxicity profile of irinotecan (CAMPTO) in patients with advanced colorectal cancer, resistant to 5-FU based chemotherapy. From October 1996 to November 1998 19 previously treated metastatic colorectal cancer patients with documented progression were recruited. Irinotecan was given at a dose of 350 mg/m2 i.v. over 90 min. every 3 week. Tumor response and toxicity were assessed using WHO criteria. Median age: 59.7 years (42-72). Tumor sites: 12/19 colon, 7/19 rectum. 11/19 patients had 1 metastatic site, 8/19 had 2 or more metastatic sites. CR: 0/19, PR: 3/19, MR: 2/19, SD: 10/19, PD: 4/19. Median time to progression was 9.1 months (range 1.5-22). The overall median survival was 15.5 months (range 2.5-37). Grade 3-4 delayed diarrhoea occurred in 26.3{\%} of patients. Grade 3 neutropenia occurred in 15.7{\%} of patients. Preliminary results confirm the clinical value of irinotecan in 5-FU resistant metastatic colorectal cancer with tolerable toxicity profile. Irinotecan should be considered as the basic chemotherapeutic agent for second line treatment of metastatic colorectal cancer.",
author = "K. Krist{\'o} and J. Izs{\'o} and G. Balatoni and J. Lohinszky and E. Farcz{\'a}di and J. Sz{\'a}nt{\'o} and Kofi, {A. P.} and T. Pint{\'e}r",
year = "2000",
month = "8",
day = "13",
language = "Hungarian",
volume = "141",
pages = "1817--1820",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "33",

}

TY - JOUR

T1 - Irinotecan--második vonalbeli kezeléssel szerzett tapasztalatok elórehaladott colorectalis daganatokban.

AU - Kristó, K.

AU - Izsó, J.

AU - Balatoni, G.

AU - Lohinszky, J.

AU - Farczádi, E.

AU - Szántó, J.

AU - Kofi, A. P.

AU - Pintér, T.

PY - 2000/8/13

Y1 - 2000/8/13

N2 - The prognosis for patients with advanced colorectal cancer who fail to respond to a 5-FU based therapy is poor. About 7% response rate can be achieved with second line therapeutic regiments, the overall survival is about 6-7 months. The aim of authors was to assess the efficacy and toxicity profile of irinotecan (CAMPTO) in patients with advanced colorectal cancer, resistant to 5-FU based chemotherapy. From October 1996 to November 1998 19 previously treated metastatic colorectal cancer patients with documented progression were recruited. Irinotecan was given at a dose of 350 mg/m2 i.v. over 90 min. every 3 week. Tumor response and toxicity were assessed using WHO criteria. Median age: 59.7 years (42-72). Tumor sites: 12/19 colon, 7/19 rectum. 11/19 patients had 1 metastatic site, 8/19 had 2 or more metastatic sites. CR: 0/19, PR: 3/19, MR: 2/19, SD: 10/19, PD: 4/19. Median time to progression was 9.1 months (range 1.5-22). The overall median survival was 15.5 months (range 2.5-37). Grade 3-4 delayed diarrhoea occurred in 26.3% of patients. Grade 3 neutropenia occurred in 15.7% of patients. Preliminary results confirm the clinical value of irinotecan in 5-FU resistant metastatic colorectal cancer with tolerable toxicity profile. Irinotecan should be considered as the basic chemotherapeutic agent for second line treatment of metastatic colorectal cancer.

AB - The prognosis for patients with advanced colorectal cancer who fail to respond to a 5-FU based therapy is poor. About 7% response rate can be achieved with second line therapeutic regiments, the overall survival is about 6-7 months. The aim of authors was to assess the efficacy and toxicity profile of irinotecan (CAMPTO) in patients with advanced colorectal cancer, resistant to 5-FU based chemotherapy. From October 1996 to November 1998 19 previously treated metastatic colorectal cancer patients with documented progression were recruited. Irinotecan was given at a dose of 350 mg/m2 i.v. over 90 min. every 3 week. Tumor response and toxicity were assessed using WHO criteria. Median age: 59.7 years (42-72). Tumor sites: 12/19 colon, 7/19 rectum. 11/19 patients had 1 metastatic site, 8/19 had 2 or more metastatic sites. CR: 0/19, PR: 3/19, MR: 2/19, SD: 10/19, PD: 4/19. Median time to progression was 9.1 months (range 1.5-22). The overall median survival was 15.5 months (range 2.5-37). Grade 3-4 delayed diarrhoea occurred in 26.3% of patients. Grade 3 neutropenia occurred in 15.7% of patients. Preliminary results confirm the clinical value of irinotecan in 5-FU resistant metastatic colorectal cancer with tolerable toxicity profile. Irinotecan should be considered as the basic chemotherapeutic agent for second line treatment of metastatic colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=17144470411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144470411&partnerID=8YFLogxK

M3 - Article

VL - 141

SP - 1817

EP - 1820

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 33

ER -